A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

Inclusion Criteria:

• Diagnosed with type 2 diabetes (T2D) greater than or equal to (>=) 180 days prior tothe day of screening
• HbA1c from 7.5%-10.5% (58-91 millimoles per mole [mmol/mol]) (both inclusive)
• Treated with once daily or twice daily basal insulin (minimum of 0.25 internationalunits per kilograms per day (IU/kg/day) or 20 IU/day) without concomitantglucagon-like peptide-1 receptor agonists (GLP-1 RA) >= 90 days prior to the day ofscreening with or without any of the following antidiabetic drugs/regimens with stabledoses >= 90 days prior to screening: metformin, sulfonylureas, meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose Cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors. Oral combinationproducts (for the allowed individual oral anti-diabetic drugs)

Exclusion Criteria:

• Presence or history of pancreatitis (acute or chronic) within 180 days beforescreening
• Myocardial infarction, stroke, hospitalisation for unstable angina pectoris ortransient ischaemic attack within 180 days prior to the day of screening and betweenscreening and initiation
• Chronic heart failure classified as being in New York Heart Association (NYHA) ClassIV at screening
• Planned coronary, carotid or peripheral artery revascularization
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified bya fundus examination performed within the past 90 days prior to screening or in theperiod between screening and initiation. Pharmacological pupil-dilation is arequirement unless using a digital fundus photography camera specified for non-dilatedexamination